We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




A Novel Liquid Biopsy Technique for Diagnosis of Cancers in Children

By LabMedica International staff writers
Posted on 07 Jun 2021
A novel liquid biopsy technique for cancer diagnosis in pediatric patients detects and quantifies epigenetic signatures based on cell-free DNA (cfDNA) fragmentation patterns.

Liquid biopsy analysis of circulating cfDNA from peripheral blood has emerged as a valuable diagnostic tool in oncology, since sample collection is quick and minimally invasive. More...
In cancer patients, cfDNA consists in part of cancer-derived circulating tumor DNA (ctDNA), and it has been shown that tumor-related genetic and epigenetic alterations can be detected by analyzing cfDNA in cancer patients. As a consequence, cfDNA analysis holds great promise for precision oncology and personalized therapies, and is currently being evaluated in a broad range of clinical studies. However, the use of liquid biopsy for childhood cancers has so far been hampered by the fact that many childhood tumors have few genetic alterations that are detectable in cfDNA.

To improve this situation, investigators at St. Anna Children's Cancer Research Institute (Vienna, Austria) introduced an integrated genetic/epigenetic analysis method and demonstrated its utility on 241 deep whole-genome sequencing profiles of 95 patients with Ewing sarcoma and 31 patients with other pediatric sarcomas. Ewing sarcoma is a type of cancer that may be a bone sarcoma or a soft-tissue sarcoma. Symptoms may include swelling and pain at the site of the tumor, fever, and a bone fracture. Ewing sarcoma occurs most often in teenagers and young adults and represents 2% of childhood cancers.

The method introduced in the current study was based on analysis of the fragmentation patterns of the small DNA fragments leaked by tumors into the blood stream, which reflected the unique epigenetic signature of many childhood cancers.

Results revealed that tumor DNA in the blood of patients with Ewing sarcoma was highly and characteristically fragmented. The investigators identified an Ewing sarcoma-specific epigenetic signature among regional fragmentation patterns across the genome, and presented a bioinformatic method for accurate quantification of these epigenetic signatures in cfDNA. Ultimately, they conducted one of the largest cfDNA sequencing studies for childhood cancer, resulting in a detailed genetic and epigenetic analysis of Ewing sarcoma tumors using liquid biopsies.

"We previously identified unique epigenetic signatures of Ewing sarcoma. We reasoned that these characteristic epigenetic signatures should be preserved in the fragmentation patterns of tumor-derived DNA circulating in the blood. This would provide us with a much-needed marker for early diagnosis and tumor classification using the liquid biopsy concept," said senior author Dr. Eleni Tomazou, principal investigator of the epigenome-based precision medicine group at St. Anna Children's Cancer Research Institute.

The current study unveiled the LIQUORICE algorithm for detecting circulating tumor DNA based on cancer-specific chromatin signatures. "By feeding these machine learning algorithms with our extensive whole genome sequencing data of tumor-derived DNA in the blood stream, the analysis becomes highly sensitive and in many instances outperforms conventional genetic analyses", said Dr. Tomazou. "Right now, most patients receive very high doses of chemotherapy, while some patients may be cured already with a less severe therapy, which would reduce their risk of getting other cancers later in life. There is a real medical need for adaptive clinical trials and personalized treatment of bone tumors in children."

The pediatric liquid biopsy study was published in the May 28, 2021, online edition of the journal Nature Communications.

Related Links:
St. Anna Children's Cancer Research Institute


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.